Skip to content
Download PDF

Vascular Dementia

Chapter 444 | Part 13: Neurologic Disorders · Part 13 – Neurologic Disorders · Chapter 444

Key Clinical Points

  1. Vascular dementia is now broadly defined as Vascular Contributions to Cognitive Impairment and Dementia (VCID), reflecting the impact of cerebral vasculature pathology on age-related cognitive decline, whether in isolation or with neurodegenerative processes.
  2. Mixed dementias (vascular + neurodegenerative) are more prevalent than single-etiology dementias and represent the rule rather than the exception.
  3. Approximately 50% of stroke survivors demonstrate cognitive impairment, with risk increasing over longer periods of follow-up.
  4. The SPRINT-MIND trial showed that targeting systolic blood pressure (SBP) <120 mmHg reduced mild cognitive impairment (HR 0.81) and combined MCI/dementia (HR 0.85).
  5. MRI markers for cerebral small vessel disease include: Lacunar infarcts (3–15 mm), Microinfarcts (<3 mm), Cerebral microbleeds (T2*), and White Matter Hyperintensities (FLAIR).
  6. Arteriolosclerosis affects deep penetrating vessels (thalamus, basal ganglia, brainstem); Cerebral Amyloid Angiopathy (CAA) affects superficial lobar regions (cerebral cortex, subcortical white matter, cerebral convexity subarachnoid space).
  7. Strategic infarcts in specific locations—thalamus, medial temporal cortex, anterior corpus callosum, or dominant-side angular gyrus—can sufficiently impair episodic memory and functional skills to meet criteria for dementia.
  8. Poststroke cognitive decline occurs even in patients with good initial recovery due to ongoing disease effects and loss of 'cognitive reserve'.
  9. The Framingham Study showed a significant decrease in dementia hazard rates (from 3.6 to 2.0 per 100 persons) over several decades, correlating with improved hypertension control.
  10. Advanced imaging like Diffusion Tensor MRI (DTI) and the PSMD metric can quantify white matter disconnection associated with cognitive performance and gait speed.

DEFINITION & OVERVIEW

• Traditional Definition: Historically used to describe dementia cases primarily due to one or more symptomatic strokes. • Modern Definition (VCID): Vascular Contributions to Cognitive Impairment and Dementia; a broader term encompassing the full impact of cerebrovascular disease on age-related cognitive decline. • Prevalence: Vascular dementia is typically the second most frequent cause of dementia, surpassed only by Alzheimer's disease. • Mixed Dementias: Combination of vascular and neurodegenerative features; these are more prevalent than single-etiology dementias. • Cognitive Impact: Stroke patients with good initial recovery still demonstrate accelerated poststroke cognitive decline due to ongoing disease effects and loss of cognitive reserve.

Subtypes of Cerebrovascular Disease Associated with VCID

• Large Cerebral Strokes: Symptomatic ischemic or hemorrhagic strokes; impairment is a function of size and location. • Strategic Infarcts: Specific locations (thalamus, medial temporal cortex, anterior corpus callus, or dominant-side angular gyrus) → sufficient to meet memory-based criteria for dementia. • Cerebral Small-Vessel Disease (CSVD): Often clinically asymptomatic until cognitive decline is noted. • Arteriolosclerosis: ◦ Pathology: Thickening of arterioles due to infiltration of plasma proteins into the vessel wall. ◦ Location: Deep penetrating vessels (thalamus, basal ganglia, brainstem). • Cerebral Amyloid Angiopathy (CAA): ◦ Pathology: β-amyloid peptide deposition in small cerebral arteries, arterioles, and capillaries; leads to loss of normal wall structure. ◦ Location: Superficial lobar regions (cerebral cortex, subcortical white matter, cerebral convexity subarachnoid space).

EPIDEMIOLOGY

• Geographic/Ethnic Variability: ◦ Higher incidence of intracranial atherosclerosis in Asians, Hispanics, and African Americans. ◦ Whites may have more extracranial disease. • Framingham Study Trends: 5-year age- and sex-adjusted cumulative hazard rates for dementia dropped from 3.6 (1970s–80s) to 2.0 (2000s–2010s), correlating with improved hypertension control.

• Access to Care: Higher prevalence in populations with limited medical access where risk factors are undertreated. • Arteriolosclerosis Risk Factors: Age, hypertension, and diabetes mellitus. • Cerebral Amyard Angiopathy Risk Factors: Advancing age.

ETIOLOGY & PATHOPHYSIOLOGY

• Mechanism of Impairment: ◦ Large strokes → irreversible injury to discrete areas. ◦ Small-vessel disease → cumulative impact of small distributed brain injuries. • MRI Markers of CSVD: ◦ Lacunar Infarcts: 3–15 mm; hyperintense rim/hypointense core on FLAIR. ◦ Microinfarcts: <3 mm; more numerous than lacunes; visible as punctate hyperintensities on DWI. ◦ Cerebral Microbleeds: Detected via T2 due to paramagnetic effects of iron products. ◦ White Matter Hyperintensities (WMH): Ubiquitous in aging; markers of gliosis, demyelination, or increased water content. • Binswanger's Disease:* Also known as subcortical arteriosclerotic encephalopathy; characterized by severe white matter injury and gradual cognitive deterioration.

MRI Markers and Imaging Findings

• Lacunar Infarcts: FLAIR sequence → hyper1ense rim, hypointense core (thalamus). • Acute Microinfarcts: DWI sequence → small hyperintense lesion (centrum semiovale). • Cerebral Microbleeds (Deep): T2 sequence → hypointense lesions in pons (Arteriolosclerosis). • Cerebral Microbleeds (Lobar): T2 sequence → hypointense lesions in lobar regions (CAA). • White Matter Hyperintensities: FLAIR/T2-weighted → confluent diffuse hyperintensities. • Diffusion Tensor MRI: Measures white matter structural integrity; correlates with cognitive performance and gait speed. • PSMD Metric: Quantify white matter disconnection via peak width of the skeletonized mean diffusivity histogram.

CLINICAL FEATURES

• Cognitive Domains Affected: ◦ Episodic memory (especially in strategic infarcts). ◦ Executive function. ◦ Processing speed. ◦ Visuospatial performance. • Poststroke Cognitive Decline: ◦ Patients with good initial recovery still show accelerated decline. ◦ Example: Change from +0.021 points/year (pre-stroke) to -0.035 points/year (post-stroke) on the six-item screener global cognitive function scale. ◦ Mechanism: Ongoing disease effects + loss of cognitive reserve.

Cognitive Decline Trajectories

• Risk Factors for Decline: ◦ Size and location of infarcts. ◦ Number of strokes. ◦ Loss of cognitive reserve → less resilience to age-related disorders.

DIFFERENTIAL DIAGNOSIS

• Mixed Dementia: ◦ Combination of cerebrovascular and neurodegenerative (e.g., Alzheimer's) lesions. ◦ Result: Greater cognitive/functional impairment than expected from either mechanism alone.

Mixed Dementia Considerations

• Synergistic Effect: Co-occurrence of vascular and neurodegenerative pathology → accelerated decline.

INVESTIGATIONS & DIAGNOSIS

  1. Clinical Assessment: Evaluate cognitive domains (memory, executive function, processing speed, visuospatial performance).
  2. Imaging Selection based on suspected pathology: ◦ FLAIR/T2-weighted MRI: Identify White Matter Hyperintensities (WMH) and Lacunar Infarcts (3–15 mm). ◦ Diffusion-Weighted Imaging (DWI): Identify acute microinfarcts (<3 mm). ◦ T2*-weighted MRI: Differentiate between Arteriolosclerosis (deep microbleeds) and Cerebral Amyloid Angiopathy (lobar microbleeds).
  3. Advanced Metrics: ◦ Diffusion Tensor MRI: Assess white matter structural integrity (correlates with cognitive performance and gait speed). ◦ PSM Metric: Quantify white matter disconnection via peak width of the skeletonized mean diffusivity histogram.

MANAGEMENT & TREATMENT

  1. Risk Factor Management: ◦ Target hypertension and diabetes mellitus.
  2. Blood Pressure Control: ◦ SPRINT-MIND Trial: Target SBP <120 mmHg → reduced risk of mild cognitive impairment (HR 0.81) and combined MCI/dementia (HR 0.85).

Prevention

• Early Intervention: Identifying markers of small-vessel disease early may allow for interventions to slow or prevent vascular brain injury.

PROGNOSIS & COMPLICATIONS

• Cognitive Decline Trajectories: ◦ Patients with good initial recovery still show accelerated decline. ◦ Example: Change from +0.021 points/year (pre-stroke) to -0.035 points/year (post-stroke) on the six-item screener global cognitive function scale.

SPECIAL CONSIDERATIONS

• Cerebrovascular Reactivity: ◦ Potential outcome marker for identifying disease-modifying interventions. ◦ May become abnormal decades before appearance of structural brain injury.

KEY PEARLS & CLINICAL TRAPS

• VCID vs. Vascular Dementia: VCID is the broader, more modern term including both isolated and mixed pathologies. • Microbleed Localization: Deep → Arteriolosclerosis; Lobar → Cerebral Amyloid Angiopathy. • Cognitive Reserve: Loss of reserve explains why patients with 'good' recovery still experience rapid decline. • Symptom Specificity: Strategic infarcts (e.g., thalamus, medial temporal cortex, anterior corpus callosum, or dominant-side angular gyrus) → sufficient to meet memory-based criteria for dementia.